Clinical Trial Results:
Taste and palatability of Orfadin suspension. An open, non-controlled 3-day study in pediatric patients with hereditary tyrosinemia type 1 treated with Orfadin.
Summary
|
|
EudraCT number |
2012-002286-36 |
Trial protocol |
DE GB |
Global end of trial date |
01 Mar 2013
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
20 Jun 2016
|
First version publication date |
06 Aug 2015
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
Sobi.NTBC-002
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01734889 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Swedish Orphan Biovitrum AB
|
||
Sponsor organisation address |
Tomtebodavägen 23, Stockholm, Sweden, 11276
|
||
Public contact |
Medical Director, Swedish Orphan Biovitrum AB, 0046 86970000, anders.broijersen@sobi.com
|
||
Scientific contact |
Medical Director, Swedish Orphan Biovitrum AB, 0046 86970000, anders.broijersen@sobi.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-000784-PIP02-11 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 Mar 2013
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
22 Feb 2013
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
01 Mar 2013
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To determine the acceptability of the suspension in the pediatric population.
|
||
Protection of trial subjects |
Monitoring procedures performed prior to, during, and upon completion of the study have verified that this study was conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
09 Nov 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 12
|
||
Country: Number of subjects enrolled |
France: 2
|
||
Country: Number of subjects enrolled |
Germany: 4
|
||
Worldwide total number of subjects |
18
|
||
EEA total number of subjects |
18
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
6
|
||
Children (2-11 years) |
6
|
||
Adolescents (12-17 years) |
6
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
- | ||||||
Pre-assignment
|
|||||||
Screening details |
Patients less than 18 years old with HT-1 currently managed on Orfadin (nitisinone) capsules. | ||||||
Period 1
|
|||||||
Period 1 title |
Overall study (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Blinding implementation details |
The objective of this study was to demonstrate that taste and palatability of the suspension are acceptable to the patients, especially those who are too young to swallow capsules. The objective was not to compare the taste of the suspension with that of the capsules,nor to evaluate different flavors of the suspension. Therefore, an open, non-randomized designwas used.
|
||||||
Arms
|
|||||||
Arm title
|
Overall study | ||||||
Arm description |
All subjects receive the same study treatment | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Orfadin
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Oral suspension
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
Orfadin suspension 4 mg/mL.
Twice daily for three days, dose as current with Orfadin capsules
|
||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall study
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Safety analysis set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Safety analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
All subjects who received at least one dose of IMP
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Full analysis set (FAS)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
All subjects who received at least one dose of IMP and had at least one
taste or acceptability assessment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Per protocol analysis set (PPAS)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Per protocol | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Subjects who had completed the questionnaire at all occasions
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
< 5 years (FAS)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Sub-group analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Analyses of the data were made using subgroups <5 years and 5 to <18 years considered more appropriate for evaluation of taste and palatability and also related to the children’s ability to swallow capsules, as described in the clinical study report Sections 6.7.3.3 and 6.7.3.4
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
5 - <18 years (FAS)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Sub-group analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Analyses of the data were made using subgroups <5 years and 5 to <18 years considered more appropriate for evaluation of taste and palatability and also related to the children’s ability to swallow capsules, as described in the clinical study report Sections 6.7.3.3 and 6.7.3.4
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Overall study
|
||
Reporting group description |
All subjects receive the same study treatment | ||
Subject analysis set title |
Safety analysis set
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
All subjects who received at least one dose of IMP
|
||
Subject analysis set title |
Full analysis set (FAS)
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
All subjects who received at least one dose of IMP and had at least one
taste or acceptability assessment
|
||
Subject analysis set title |
Per protocol analysis set (PPAS)
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Subjects who had completed the questionnaire at all occasions
|
||
Subject analysis set title |
< 5 years (FAS)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Analyses of the data were made using subgroups <5 years and 5 to <18 years considered more appropriate for evaluation of taste and palatability and also related to the children’s ability to swallow capsules, as described in the clinical study report Sections 6.7.3.3 and 6.7.3.4
|
||
Subject analysis set title |
5 - <18 years (FAS)
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Analyses of the data were made using subgroups <5 years and 5 to <18 years considered more appropriate for evaluation of taste and palatability and also related to the children’s ability to swallow capsules, as described in the clinical study report Sections 6.7.3.3 and 6.7.3.4
|
|
|||||||||
End point title |
Taste score on Day 3 for subjects aged 5 - <18 years (Median) [1] | ||||||||
End point description |
Subjects who were 5 to < 18 years of age were asked to rate the taste of the suspension on 5-graded verbal/numerical scales
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
Taste score at the last dose of the suspension on Day 3
|
||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analyses was performed. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Taste score on Day 3 for subjects 5 to < 18 years (Categories) [2] | ||||||||||||||||
End point description |
Subjects who were 5 to < 18 years of age were asked to rate the taste of the suspension on 5-graded verbal/numerical scales
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Taste score for the last dose on Day 3
|
||||||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analyses was performed. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Acceptability score on Day 3 for subjects < 5 years (Median) [3] | ||||||||
End point description |
For subjects younger than 5 years of age, one of the parents rated the child’s acceptability of the suspension on a verbal/numerical scale.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
Acceptability score at the last dose of the suspension on Day 3
|
||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analyses was performed. |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Acceptability score on Day 3 for subjects < 5 years (Categories) [4] | ||||||||||||||||
End point description |
For subjects younger than 5 years of age, one of the parents rated the child’s acceptability of the suspension on a verbal/numerical scale.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Acceptability score at the last dose of the suspension on Day 3
|
||||||||||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analyses was performed. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Taste score on Day 1 for subjects aged 5 - <18 years (Median) | ||||||||
End point description |
Subjects who were 5 to < 18 years of age were asked to rate the taste of the suspension on 5-graded verbal/numerical scales
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 1
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Taste score on Day 1 for subjects aged 5 - <18 years (Categories) | ||||||||||||||||
End point description |
Subjects who were 5 to < 18 years of age were asked to rate the taste of the suspension on 5-graded verbal/numerical scales
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Day 1
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Taste score on Day 2 for subjects aged 5 - <18 years (Median) | ||||||||
End point description |
Subjects who were 5 to < 18 years of age were asked to rate the taste of the suspension on 5-graded verbal/numerical scales
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 2
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Taste score on Day 2 for subjects aged 5 - <18 years (Categories) | ||||||||||||||||
End point description |
Subjects who were 5 to < 18 years of age were asked to rate the taste of the suspension on 5-graded verbal/numerical scales
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Day 2
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Acceptability score Day 1 for subjects < 5 years (Median) | ||||||||
End point description |
For subjects younger than 5 years of age, one of the parents rated the child’s acceptability of the suspension on a verbal/numerical scale.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 1
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Acceptability score Day 1 for subjects < 5 years (Categories) | ||||||||||||||||
End point description |
For subjects younger than 5 years of age, one of the parents rated the child’s acceptability of the suspension on a verbal/numerical scale.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Day 1
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Acceptability score Day 2 for subjects < 5 years (Median) | ||||||||
End point description |
For subjects younger than 5 years of age, one of the parents rated the child’s acceptability of the suspension on a verbal/numerical scale.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 2
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Acceptability score on Day 2 for subjects < 5 years (Categories) | ||||||||||||||||
End point description |
For subjects younger than 5 years of age, one of the parents rated the child’s acceptability of the suspension on a verbal/numerical scale.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Day 2
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Palatability score on Day 1 for subjects aged 5 - <18 years (Median) | ||||||||
End point description |
Subjects who were 5 to < 18 years of age were asked to rate the palatability of the suspension on 5-graded verbal/numerical scales
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 1
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Palatability score on Day 1 for subjects aged 5 - <18 years (Categories) | ||||||||||||||||
End point description |
Subjects who were 5 to < 18 years of age were asked to rate the palatability of the suspension on 5-graded verbal/numerical scales
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Day 1
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Palatability score on Day 2 for subjects aged 5 - <18 years (Median) | ||||||||
End point description |
Subjects who were 5 to < 18 years of age were asked to rate the palatability of the suspension on 5-graded verbal/numerical scales
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 2
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Palatability score on Day 2 for subjects aged 5 - <18 years (Categories) | ||||||||||||||||
End point description |
Subjects who were 5 to < 18 years of age were asked to rate the palatability of the suspension on 5-graded verbal/numerical scales
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Day 2
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Palatability score on Day 3 for subjects aged 5 - <18 years (Median) | ||||||||
End point description |
Subjects who were 5 to < 18 years of age were asked to rate the palatability of the
suspension on 5-graded verbal/numerical scales
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Day 3
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Palatability score on Day 3 for subjects aged 5 - <18 years (Categories) | ||||||||||||||||
End point description |
Subjects who were 5 to < 18 years of age were asked to rate the palatability of the suspension on 5-graded verbal/numerical scales
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Day 3
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Overall acceptability | ||||||||||
End point description |
At the end of the treatment period (last dose on Day 3), an overall question was filled out by the subject if possible, otherwise by the parent: “Would you/your child accept taking the new medicine again?”. The response alternatives were “Yes” or “No”.
|
||||||||||
End point type |
Secondary
|
||||||||||
End point timeframe |
After last dose on Day 3
|
||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
The AE reporting period began on administration of the first dose of IMP and ended at the last study visit (1 w after last dose of IMP).The SAE reporting period began when the subject had signed the informed consent until 28 days past the last dose of IMP
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
All directly observed AEs, and all AEs spontaneously reported by the subject, were recorded in the CRF. In addition, each subject was questioned about AEs during the follow-up telephone contact. The question asked was “Since you/your child began taking the Orfadin suspension, have you/has your child had any health problems?”
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
15.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
<5 years
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
5-<18 years
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Safety analysis set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |